Related Experiment Video
Updated: Oct 1, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors
Amol M Vibhute1, Hide-Nori Tanaka1, Sushil K Mishra2
1Institute for Glyco-core Research (iGCORE), Gifu University, Gifu 501-1193, Japan.
Background:
N-Glycan branching regulates various functions of glycoproteins. N-Acetylglucosaminyltransferase V (GnT-V) is a GlcNAc transferase that acts on N-glycans and the GnT-V-producing branch is highly related to cancer progression. This indicates that specific GnT-V inhibitors may be drug candidates for cancer treatment. To design novel GnT-V inhibitors, we focused on the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V. On the basis of the catalytic pocket structure, we hypothesized that UDP-GlcNAc analogs with increasing hydrophobicity may be GnT-V inhibitors.
Methods:
We chemically synthesized 10 UDP-GlcNAc analogs in which one or two phosphate groups were replaced with hydrophobic groups. To test these compounds, we set up an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes. Using this system, we assessed the inhibitory effects of the synthesized compounds on GnT-V and their specificity.
Results:
Several UDP-GlcNAc analogs inhibited GnT-V activity, although the inhibition potency was modest. Compared with other GnTs, these compounds showed a preference for GnT-V, which suggested that GnT-V was relatively tolerant of hydrophobicity in the donor substrate. Docking models of the inhibitory compounds with GnT-V suggested the mechanisms of how these compounds interacted with GnT-V and inhibited its action.
Conclusions:
Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
General Significance:
Our findings provide new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate.
Insights
Novel UDP-GlcNAc analogs with increased hydrophobicity were synthesized and tested. These compounds showed modest inhibition and selectivity for N-Acetylglucosaminyltransferase V (GnT-V), suggesting a promising strategy for cancer drug development.
Area of Science:
- Glycobiology
- Enzyme Inhibitor Design
- Cancer Therapeutics
Background:
- N-Glycan branching influences glycoprotein functions.
- N-Acetylglucosaminyltransferase V (GnT-V) activity is linked to cancer progression.
- Targeting GnT-V with inhibitors is a potential cancer treatment strategy.
Purpose of the Study:
- To design novel GnT-V inhibitors by modifying the donor substrate UDP-GlcNAc.
- To explore the hypothesis that increased hydrophobicity of UDP-GlcNAc analogs may inhibit GnT-V.
- To investigate the recognition mechanism of UDP-GlcNAc by GnT-V.
Main Methods:
- Chemical synthesis of 10 UDP-GlcNAc analogs with hydrophobic modifications.
- Development of an HPLC-based enzyme assay system to measure GnT-I-V activity.
- Assessment of inhibitory effects and specificity of synthesized compounds on GnT-V using purified enzymes.
Main Results:
- Several synthesized UDP-GlcNAc analogs demonstrated inhibition of GnT-V activity.
- The compounds exhibited selectivity for GnT-V over other GnTs, indicating GnT-V's tolerance to substrate hydrophobicity.
- Docking models provided insights into the interaction mechanisms between inhibitors and GnT-V.
Conclusions:
- Chemical modification of the UDP-GlcNAc donor substrate is a viable strategy for developing selective GnT-V inhibitors.
- Findings offer new perspectives on GnT inhibitor design and substrate recognition.
More Related Videos
08:46Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
Published on: July 26, 2018
11:08Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
Published on: February 5, 2018
Related Concept Videos
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Peptidoglycan Synthesis
Preparation of 1° Amines: Gabriel Synthesis
Strong bases like NaOH or KOH deprotonate the phthalimide to form the corresponding anion, which acts as a nucleophile. Further, the anion attacks an...